Early studies using the pan-BCL-2 inhibitor ABT-737 in neuroblastoma cell lines revealed a synergistic cytotoxicity with fenretinide, a synthetic retinoid derivative that inhibits cancer-cell line growth, while the combination also increased event-free survival in an orthotopic mouse model of neuroblastoma [90]. Here, BCL2 is linked to cancer.